These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38811761)

  • 1. Trans-nuclease activity of Cas9 activated by DNA or RNA target binding.
    Chen J; Chen Y; Huang L; Lin X; Chen H; Xiang W; Liu L
    Nat Biotechnol; 2024 May; ():. PubMed ID: 38811761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naked-eye detection of site-specific ssRNA and ssDNA using PAMmer-assisted CRISPR/Cas9 coupling with exponential amplification reaction.
    Wang X; Chen X; Chu C; Deng Y; Yang M; Huo D; Xu F; Hou C; Lv J
    Talanta; 2021 Oct; 233():122554. PubMed ID: 34215057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. trans Single-Stranded DNA Cleavage via CRISPR/Cas14a1 Activated by Target RNA without Destruction.
    Wei Y; Yang Z; Zong C; Wang B; Ge X; Tan X; Liu X; Tao Z; Wang P; Ma C; Wan Y; Li J
    Angew Chem Int Ed Engl; 2021 Nov; 60(45):24241-24247. PubMed ID: 34553468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence.
    Babu K; Kathiresan V; Kumari P; Newsom S; Parameshwaran HP; Chen X; Liu J; Qin PZ; Rajan R
    Biochemistry; 2021 Dec; 60(49):3783-3800. PubMed ID: 34757726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new family of CRISPR-type V nucleases with C-rich PAM recognition.
    Urbaitis T; Gasiunas G; Young JK; Hou Z; Paulraj S; Godliauskaite E; Juskeviciene MM; Stitilyte M; Jasnauskaite M; Mabuchi M; Robb GB; Siksnys V
    EMBO Rep; 2022 Dec; 23(12):e55481. PubMed ID: 36268581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features.
    Lin J; Fuglsang A; Kjeldsen AL; Sun K; Bhoobalan-Chitty Y; Peng X
    Nucleic Acids Res; 2020 Oct; 48(18):10470-10478. PubMed ID: 32960267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmable RNA recognition and cleavage by CRISPR/Cas9.
    O'Connell MR; Oakes BL; Sternberg SH; East-Seletsky A; Kaplan M; Doudna JA
    Nature; 2014 Dec; 516(7530):263-6. PubMed ID: 25274302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes.
    Ma E; Harrington LB; O'Connell MR; Zhou K; Doudna JA
    Mol Cell; 2015 Nov; 60(3):398-407. PubMed ID: 26545076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity.
    Chen JS; Ma E; Harrington LB; Da Costa M; Tian X; Palefsky JM; Doudna JA
    Science; 2018 Apr; 360(6387):436-439. PubMed ID: 29449511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Unwinding Is the Primary Determinant of CRISPR-Cas9 Activity.
    Gong S; Yu HH; Johnson KA; Taylor DW
    Cell Rep; 2018 Jan; 22(2):359-371. PubMed ID: 29320733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-dependent RNA targeting by CRISPR-Cas9.
    Strutt SC; Torrez RM; Kaya E; Negrete OA; Doudna JA
    Elife; 2018 Jan; 7():. PubMed ID: 29303478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
    Jinek M; Chylinski K; Fonfara I; Hauer M; Doudna JA; Charpentier E
    Science; 2012 Aug; 337(6096):816-21. PubMed ID: 22745249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for RNA-guided DNA cleavage by IscB-ωRNA and mechanistic comparison with Cas9.
    Schuler G; Hu C; Ke A
    Science; 2022 Jun; 376(6600):1476-1481. PubMed ID: 35617371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Structures and Mechanisms.
    Jiang F; Doudna JA
    Annu Rev Biophys; 2017 May; 46():505-529. PubMed ID: 28375731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic characterization of Cas9 enzymes.
    Liu MS; Gong S; Yu HH; Taylor DW; Johnson KA
    Methods Enzymol; 2019; 616():289-311. PubMed ID: 30691648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.